News

Good news doesn’t cancel out the bad stuff
Enlarge image

BusinessSwitzerland

Good news doesn’t cancel out the bad stuff

17.04.2012 - Swiss Addex has announced positive results from ongoing studies.
Yet it is dismissing 28 workers – perhaps a delayed effect from bad news last fall.

Geneva – On April 16, only three days after the announcement that its ongoing restructuring efforts will result in laying off 28 employees, Swiss Addex Therapeutics reported positive preclinical data for its lead GABA-B receptor modulator. The orally administered small molecule ADX71441 is a positive allosteric modulator (PAM). In both guinea pig and mouse studies, the selective activation of GABA-B alleviated symptoms in disease-relevant models of  overactive bladder (OAB). While Addex aims for IND/CTA filing before the end of the year, another PAM is already being evaluated in a Phase 2a clinical trial by Addex’ partner Janssen Pharmaceuticals. Activating the glutamate receptor mGluR2 with ADX71449 is being tested to treat schizophrenia.

Yet even better news was publicised in March when Addex reported that in a Phase 2a clinical trial, all key objectives had been achieved: Parkinson’s disease patients suffering from levodopa-induced dyskinesia (LID) were given oral dipraglurant, a small molecule allosteric modulator selectively inhibiting the glutamate receptor mGluR5. The compound not only proved to be safe and tolerable but also significantly reduced dyskinesia severity. In terms of sentiment, however, this news doesn’t make up for the announced workforce cut required. President and CEO of Addex, Bharatt Chowrira, said: „We deeply regret the loss of people’s jobs at Addex but we believe it is necessary to improve the operational efficiency.“

Addex was forced to sail close to the wind last November when Merck & Co. opted not to continue the joint development of ADX88178, a PAM targeting mGluR4. The drug is also assigned to treat Parkinson’s disease. The current lay-offs could very well be the delayed effects of Merck leaving Addex high and dry. 

http://www.european-biotechnology-news.com/news/news/2012-02/good-news-doesnt-cancel-out-the-bad-stuff.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products